---
title: "Effect of oral niacin on central retinal vein occlusion. | Sutter Health"
description: "Niacin may be associated with functional and anatomic improvements in eyes with CRVO. Can it be used as an adjunct therapy to intravitreal injections?"
url: "https://www.sutterhealth.org/research/publications/oral-niacin-on-central-retinal-vein-occlusion-1055312314"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Research publications](https://www.sutterhealth.org/research/publications) /
4.  Effect of oral niacin on central retinal vein occlusion.

# Effect of oral niacin on central retinal vein occlusion.

Gaynon MW, Paulus YM, Rahimy E, Alexander JL, & Mansour SE.

_Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-017-3606-0. \[Epub ahead of print\]_

2017-02-04

## Abstract

PURPOSE: Niacin, a treatment for dyslipidemia, is known to induce vasodilation as a secondary effect. Previous instances of patients with chronic central retinal vein occlusion (CRVO) and cystoid macular edema (CME) have been observed to spontaneously improve when placed on systemic niacin for hypercholesterolemia. The purpose of this study was to evaluate the effects of niacin on CRVO and associated ocular complications.

METHODS: A prospective, single-center, non-randomized, interventional case series of niacin for CRVO was conducted. Best-correct visual acuity (BCVA), central macular thickness (CMT), and ocular complications were analyzed in 50 patients over 1 year. Eight patients were controls.

RESULTS: The mean initial logMAR BCVA was 0.915, and improved with niacin to 0.745 (P = 0.12), 0.665 (P = 0.02) and 0.658 (P = 0.03) after 3, 6, and 12 months of follow-up, respectively. At baseline, mean CMT was 678.9 μm, and improved to 478.1 μm (P = 0.001), 388.6 μm (P < 0.001), and 317.4 μm (P < 0.001) for the same time points. The control group had a mean initial logMAR BCVA of 1.023, which gradually deteriorated to 1.162 (P = 0.36) after 12 months, and baseline CMT of 700.0 μm at baseline, which gradually improved to 490.9 μm (P = 0.06) after 12 months. Panretinal photocoagulation for neovascularization was required in 5 patients (13.2%) receiving niacin and 3 (37.5%) controls.

CONCLUSIONS: These data suggest that niacin may be associated with functional and anatomic improvements in eyes with CRVO. Future investigations will help ascertain whether there is a role for niacin as an adjunct therapy to intravitreal injections in the management of CRVO.

[PubMed abstract](https://www.ncbi.nlm.nih.gov/pubmed/28161829)

## Research topics

-   [Cardiovascular Diseases](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Cardiovascular+Diseases%5C%22%22)
-   [Complementary Therapies](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Complementary+Therapies%5C%22%22)
-   [Disease Management](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Disease+Management%5C%22%22)

## Related publications

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

-   Publication
    
    ### [Potentially reversible effect of niacin therapy on edema from retinal vein occlusion.](https://www.sutterhealth.org/research/publications/niacin-tx-edema-retinal-vein-occlusion-1055312424)
    
    Rahimy E, Gaynon MW, Paulus YM, Alexander JL, Mansour SE.
    
    Send to: JAMA Ophthalmol. doi: 10.1001/jamaophthalmol.2016.1028. \[Epub ahead of print\]
    
    2016 May 26
    
-   Publication
    
    ### [Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial.](https://www.sutterhealth.org/research/publications/health-status-post-tavr-corevalve-us-trial-1055312500)
    
    Osnabrugge RL, Arnold SV, Reynolds MR, Magnuson EA, Wang K, Gaudiani VA, Stoler RC, Burdon TA, Kleiman N, Reardon MJ, Adams DH, Popma JJ, Cohen DJ; CoreValve U.S. Trial Investigators.
    
    JACC Cardiovasc Interv. 8(2):315-23. doi: 10.1016/j.jcin.2014.08.016.
    
    2015 Feb 01
    
-   Publication
    
    ### [Rapid single-breath-hold 3D late gadolinium enhancement cardiac MRI using a stack-of-spirals acquisition.](https://www.sutterhealth.org/research/publications/rapid-3d-gadolinium-enhancemt-cardiac-mri-1055312461)
    
    Shin T, Lustig M, Nishimura DG, Hu BS.
    
    J Magn Reson Imaging. 40(6):1496-502. doi: 10.1002/jmri.24494. Epub 2013 Nov 15. J Magn Reson Imaging. 40(6):1496-502. doi: 10.1002/jmri.24494. Epub 2013 Nov 15. Send to:
    
    2014 Dec 02
    
-   Publication
    
    ### [Off-resonance-robust velocity-selective magnetization preparation for non-contrast-enhanced peripheral MR angiography.](https://www.sutterhealth.org/research/publications/off-reson-robust-veloc-select-magnetiz-prep-mra-1055312480)
    
    Shin T, Hu BS, Nishimura DG.
    
    Magn Reson Med. 70(5):1229-40. doi: 10.1002/mrm.24561. Epub 2012 Nov 28.
    
    2013 Nov 01
    
-   Publication
    
    ### [Non-contrast-enhanced peripheral angiography using a sliding interleaved cylinder acquisition.](https://www.sutterhealth.org/research/publications/noncontrast-enhance-periph-angiog-use-slincyl-1055312471)
    
    Kwon KT, Kerr AB, Wu HH, Hu BS, Brittain JH, Nishimura DG.
    
    Magn Reson Med. 74(3):727-38. doi: 10.1002/mrm.25452. Epub 2014 Sep 9.
    
    2015 Sep 01
    

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/oral-niacin-on-central-retinal-vein-occlusion-1055312314#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Effect of oral niacin on central retinal vein occlusion."}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/oral-niacin-on-central-retinal-vein-occlusion-1055312314#medicalscholarlyarticle","name":"Effect of oral niacin on central retinal vein occlusion.","headline":"Effect of oral niacin on central retinal vein occlusion.","abstract":"PURPOSE: Niacin, a treatment for dyslipidemia, is known to induce vasodilation as a secondary effect. Previous instances of patients with chronic central retinal vein occlusion (CRVO) and cystoid macular edema (CME) have been observed to spontaneously improve when placed on systemic niacin for hypercholesterolemia. The purpose of this study was to evaluate the effects of niacin on CRVO and associated ocular complications. METHODS: A prospective, single-center, non-randomized, interventional case series of niacin for CRVO was conducted. Best-correct visual acuity (BCVA), central macular thickness (CMT), and ocular complications were analyzed in 50 patients over 1 year. Eight patients were controls. RESULTS: The mean initial logMAR BCVA was 0.915, and improved with niacin to 0.745 (P = 0.12), 0.665 (P = 0.02) and 0.658 (P = 0.03) after 3, 6, and 12 months of follow-up, respectively. At baseline, mean CMT was 678.9 μm, and improved to 478.1 μm (P = 0.001), 388.6 μm (P \u003c 0.001), and 317.4 μm (P \u003c 0.001) for the same time points. The control group had a mean initial logMAR BCVA of 1.023, which gradually deteriorated to 1.162 (P = 0.36) after 12 months, and baseline CMT of 700.0 μm at baseline, which gradually improved to 490.9 μm (P = 0.06) after 12 months. Panretinal photocoagulation for neovascularization was required in 5 patients (13.2%) receiving niacin and 3 (37.5%) controls. CONCLUSIONS: These data suggest that niacin may be associated with functional and anatomic improvements in eyes with CRVO. Future investigations will help ascertain whether there is a role for niacin as an adjunct therapy to intravitreal injections in the management of CRVO.","description":"Niacin may be associated with functional and anatomic improvements in eyes with CRVO. Can it be used as an adjunct therapy to intravitreal injections?","keywords":["Cardiovascular Diseases","Complementary Therapies","Disease Management"],"datePublished":"2017-02-04","url":"https://www.sutterhealth.org/research/publications/oral-niacin-on-central-retinal-vein-occlusion-1055312314","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"28161829"},{"@type":"PropertyValue","propertyID":"DOI","value":"10.1007/s00417-017-3606-0"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/28161829/","https://doi.org/10.1007/s00417-017-3606-0"],"isPartOf":{"@type":"Periodical","name":"Graefes Arch Clin Exp Ophthalmol"},"author":[{"@type":"Person","name":"Gaynon MW"},{"@type":"Person","name":"Paulus YM"},{"@type":"Person","name":"Rahimy E"},{"@type":"Person","name":"Alexander JL"},{"@type":"Person","name":"Mansour SE"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Cardiovascular Diseases","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Cardiovascular+Diseases%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Complementary Therapies","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Complementary+Therapies%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Disease Management","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Disease+Management%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/oral-niacin-on-central-retinal-vein-occlusion-1055312314","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/oral-niacin-on-central-retinal-vein-occlusion-1055312314#breadcrumblist"}}}
```
